Multi-symptom Relief with Propylene Glycol-Hydroxypropyl-Guar Nanoemulsion Lubricant Eye Drops in Subjects with Dry Eye Disease: A Post-Marketing Prospective Study

被引:2
作者
Bickle, Katherine [1 ]
Miller, Jason R. [2 ]
Tauber, Joseph [3 ]
Awisi-Gyau, Deborah [4 ]
机构
[1] Procare Vis Ctr, 1955 Newark Granville Rd, Granville, OH 43023 USA
[2] Insight Res Clin LLC d b a Eyecare Profess Inc, 9711-C Sawmill Pkwy, Powell, OH 43065 USA
[3] Tauber Eye Ctr, 4400 Broadway, Suite 202, Kansas City, MO 64111 USA
[4] Alcon Res LLC, 6201 South Freeway, Ft Worth, TX 76134 USA
关键词
Artificial tears; Dry eye symptoms; Multi-symptom relief; Tired; Watery; TEAR SUPPLEMENTS; PHASE-IV; MULTICENTER; MANAGEMENT;
D O I
10.1007/s40123-023-00853-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction: The study aimed to evaluate multi-symptom relief of dry eye manifestations with the use of propylene glycol-hydroxypropyl-guar (PG-HPG) nanoemulsion lubricant eye drops, among subjects with dry eye disease (DED).Methods: This was a post-marketing, prospective, single-arm study conducted in the USA. Subjects aged >= 18 years, with tear breakup time (TBUT) <= 10 s for both eyes, dry eye questionnaire-5 (DEQ-5) "watery eyes" symptom score 1-4, symptoms of burning/stinging, sore and tired eyes as determined by impact of dry eye on everyday living-symptom bother (IDEEL-SB) questionnaire, and IDEEL-SB score 16-65 were included. Subjects were required to complete IDEEL-SB and DEQ-5 at days 0, 14 +/- 2, and 28 +/- 2, and self-administer one drop of PG-HPG four times daily for 28 +/- 2 days. Primary endpoints were change from baseline at day 28 in symptoms of sore, stinging/burning, and tired eyes on IDEEL-SB; and symptom of watery eyes on DEQ-5. Other endpoints evaluated were corneal staining and TBUT at baseline and day 28 +/- 2; symptom relief (5-point Likert scale) at day 28 +/- 2, and safety.Results: Of 119 subjects enrolled, 95 completed the study (mean +/- SD age 61.2 +/- 13.0 years; female 69.5%). Mean IDEEL-SB scores reduced significantly from baseline at day 28 for symptoms of aching/sore eyes (change from baseline - 1.0 +/- 1.1), burning/stinging eyes (change from baseline - 1.1 +/- 0.9), and tired eyes (change from baseline - 1.1 +/- 1.0) (all p < 0.0001). Mean DEQ-5 score for watery eye symptoms significantly reduced from baseline at day 28 (change from baseline - 0.9 +/- 1.0, p < 0.0001). Corneal staining at day 28 was comparable to baseline. TBUT improved from baseline to day 28. On a Likert scale, more than 50% of subjects reported relief from symptoms of sore, stinging, and burning eyes. Three (3.1%) subjects reported treatment-emergent adverse events (non-ocular).Conclusions: PG-HPG nanoemulsion lubricant eye drops significantly improved multiple dry eye symptoms in subjects with DED over 28 days, with no new safety concerns.
引用
收藏
页码:481 / 494
页数:14
相关论文
共 30 条
  • [1] Development and validation of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients
    Abetz, Linda
    Rajagopalan, Krithika
    Mertzanis, Polyxane
    Begley, Carolyn
    Barnes, Rod
    Chalmers, Robin
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2011, 9
  • [2] Formulation Considerations for the Management of Dry Eye Disease
    Agarwal, Priyanka
    Craig, Jennifer P.
    Rupenthal, Ilva D.
    [J]. PHARMACEUTICS, 2021, 13 (02) : 1 - 19
  • [3] [Anonymous], SYSTANE COMPLETE DRU
  • [4] [Anonymous], 2017, DRY EYE RED TFOS DEW, P1
  • [5] Modern approach to the treatment of dry eye, a complex multifactorial disease: a PICASSO board review
    Aragona, Pasquale
    Giannaccare, Giuseppe
    Mencucci, Rita
    Rubino, Pierangela
    Cantera, Emilia
    Rolando, Maurizio
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2021, 105 (04) : 446 - 453
  • [6] Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification
    Barabino, S.
    Bentez-Del-Castillo, J. M.
    Fuchsluger, T.
    Labetoulle, M.
    Malachkova, N.
    Meloni, M.
    Utheim, T. Paaske
    Rolando, M.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (17) : 8642 - 8652
  • [7] Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses
    Chalmers, Robin L.
    Begley, Carolyn G.
    Caffery, Barbara
    [J]. CONTACT LENS & ANTERIOR EYE, 2010, 33 (02) : 55 - 60
  • [8] Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis
    Courtin, Romain
    Pereira, Bruno
    Naughton, Geraldine
    Chamoux, Alain
    Chiambaretta, Frederic
    Lanhers, Charlotte
    Dutheil, Frederic
    [J]. BMJ OPEN, 2016, 6 (01):
  • [9] Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial
    Craig, Jennifer P.
    Muntz, Alex
    Wang, Michael T. M.
    Luensmann, Doerte
    Tan, Jacqueline
    Huarte, Sonia Trave
    Xue, Ally L.
    Jones, Lyndon
    Willcox, Mark D. P.
    Wolffsohn, James S.
    [J]. OCULAR SURFACE, 2021, 20 : 62 - 69
  • [10] TFOS DEWS II Report Executive Summary
    Craig, Jennifer P.
    Nelson, J. Daniel
    Azar, Dimitri T.
    Belmonte, Carlos
    Bron, Anthony J.
    Chauhan, Sunil K.
    de Paiva, Cintia S.
    Gomes, Jose A. P.
    Hammitt, Katherine M.
    Jones, Lyndon
    Nichols, Jason J.
    Nichols, Kelly K.
    Novack, Gary D.
    Stapleton, Fiona J.
    Willcox, Mark D. P.
    Wolffsohn, James S.
    Sullivan, David A.
    [J]. OCULAR SURFACE, 2017, 15 (04) : 802 - 812